Three arms of the study will evaluate high-dose prophylaxis, low-dose prophylaxis and on-demand dosing...Sunovion Pharmaceuticals Inc., of Marlborough, Mass., presented clinical data for Stedesa (slicarbazepine acetate), its epilepsy candidate, in a poster session at the 2010 annual meeting of the American Epilepsy Society in San Antonio

The data were published in Clinical Cancer Research...Verona Pharma plc, of London, started a higher-dose Phase II trial of RPL554, a long-acting phosphodiesterase-3/4 inhibitor for asthma

Additionally, after 12 months of receiving a single-infusion of Mydicar, patients treated with the highest dose vs...The mean duration of hospitalization in the Mydicar high-dose group during the 12-month period was 0.4 days per patient compared with 4.5 days per patient in the placebo group

Several patients enrolled in the higher-dose groups have achieved stable disease and have been enrolled in an ongoing dose-extension study...Astex Therapeutics, of Cambridge, UK, will report clinical data on three anticancer candidates at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Nov. 16-19 in Berlin

Horizon Pharma Inc., of Northbrook, Ill., said results from a long-term safety study of HZT-501, a single-tablet formulation of ibuprofen and high-dose famotidine, showed that the drug's safety was comparable to ibuprofen alone...In separate news, UCB reported data showing that the addition of Cimzia (certolizumab pegol) to current therapy was associated with a rapid clinical response, improved function and reduced disease activity in a diverse group of adult rheumatoid arthritis patients

Phase I data have shown substantial clinical activity and good tolerability among nearly 30 patients...NP2 Enkephalin, an opioid peptide being developed for chronic pain in cancer by Stockholm, Sweden's Diamyd Medical AB, performed well in a Phase I trial, demonstrating substantial, sustained pain reduction at the middle and high doses

Clinical results presented at the 15th International Congress of the World Muscle Society showed it was safe, well tolerated, reduced key inflammatory markers and had no immune response to newly produced dystrophin...Brain lesions were reduced 96 percent for high-dose ocrelizumab and 89 percent for low-dose ocrelizumab compared to placebo

Neovacs SA, of Paris, said its data safety monitoring board authorized the firm to proceed to the next higher dose of INFalpha-Kinoid in its ongoing Phase I/II trial in lupus after reviewing the data for patients administered the second dose level...Trophos SA, of Marseille, France, started clinical development of TRO40303, a mitochondria pore modulator in development to reduce cardiac reperfusion injury after myocardial infarction

At the highest dose level, AP214 markedly reduced the development of AKI by 70 percent and reduced the IL-6 response by 40 percent, compared to placebo...The initial clinical indication for Bendavia is the treatment of ischemia reperfusion injury, a common complication of interventional procedures for acute myocardial infarction

and a dose-response relationship was established, with higher doses resulting in greater reductions in pain...MAP Pharmaceuticals Inc., of Mountain View, Calif., said all four clinical trials required to support a new drug application filing for Levadex (inhaled dihydroergotamine mesylate) in acute migraine have completed enrollment

Clinical response rates at the end of treatment were 85 percent, 87 percent and 92 percent, respectively, for the low, median and high doses...Clinical response was evaluated using the Skin Infection Rating Scale

SciClone Pharmaceuticals Inc., of Foster City, Calif., and partner Sigma-Tau SpA, of Rome, said final results from a clinical study testing Zadaxin (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine Focetria (Novartis AG) showed that, when evaluated 84 days following vaccination, 60 percent of patients in the high-dose Zadaxin arm achieved seroconversion, compared to 55 percent in the vaccine-only arm...When evaluated 168 days following vaccination, 36

Data from the trial also confirmed results from an earlier Phase I, showing that BNC201 is well tolerated at high doses and free of significant side effects...Inc., of Whitehouse Station, N.J. The 12-week, randomized clinical trial evaluated Ostarine 3 mg and two doses of MK-3984 compared with placebo in 88 postmenopausal women...Data showed that the greatest clinical benefit was seen with the lowest dose, 10 mg, compared to placebo, with a statistically significant 77 percent reduction in frequency

The following data were revealed at the American Society of Clinical Oncology meeting in Chicago...Ariad Pharmaceuticals Inc., of Cambridge, Mass., said updated data from an ongoing Phase I study confirmed strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multitargeted kinase inhibitor, in heavily pretreated patients with chronic myeloid leukemia, including those with the T315I mutation of the target protein Bcr-Abl...BioTheranostics, of San Diego

At the highest dose, AP214 prevented the increase in serum creatinine by 50 percent to 60 percent and by 30 percent to 40 percent in the IL-6 response, compared with placebo...Ltd., of Jiangsu, China, said data from a clinical trial testing umbilical cord mesenchymal stem transplants in 16 patients with severe refractory systemic lupus erythematosus showed that disease activity was improved during the first three months of follow-up, and after nearly two years, most patients showed clinical

The study met its primary safety and efficacy endpoints for high dose drug vs...The primary efficacy endpoint is a composite endpoint that encompasses the simultaneous assessment of patients' clinical outcomes, exercise tolerance, heart failure symptoms, biomarkers, and cardiac function

More detailed results will be presented at the American Society of Clinical Oncology annual meeting in June...Genetix plans to initiate larger clinical studies in ALD in both the U.S...VIA Pharmaceuticals Inc., of San Francisco, and the Montreal Heart Institute announced the publication of clinical trial data from a study of VIA-2291, a 5-Lipoxygenase inhibitor in the May 19, 2010, issue of Circulation: Cardiovascular Imaging

The first clinical study, to be funded by the National Institute of Allergy and Infectious Disease, will enroll 72 healthy adult volunteers to receive injections of placebo, a lower dose or a higher dose of the investigational vaccine

KaloBios Pharmaceuticals Inc., of South San Francisco, said data from the initial clinical studies of KB001, an antibody fragment against PcrV on Pseudomonas aeruginosa, demonstrated promising therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonized with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosis...The trial met its primary endpoint of reducing sputum Pseudomonas aeruginosa density, with the